In mesolimbic and cortical regions, which binding is associated with atypical antipsychotic features?

In mesolimbic and cortical regions, which binding is associated with atypical antipsychotic features?

• A. D2 receptor binding
• B. 5-HT2A receptor binding
• C. D1 receptor binding
• D. NMDA receptor binding

Answer: (A)

Dopamine D2 receptor binding in the mesolimbic and cortical pathways is what mediates the antipsychotic effects in those brain regions. Blocking D2 receptors reduces the dopamine overactivity that contributes to positive symptoms, which is why D2 antagonism is central to antipsychotic action. Atypical antipsychotics differ by adding other receptor interactions, especially 5-HT2A antagonism, which helps modulate dopamine release in neighboring circuits and reduces motor side effects. So the D2 binding is the key lever for the antipsychotic effect in these regions, with the atypical advantage coming from the broader receptor profile that includes 5-HT2A inhibition. Other bindings, like NMDA receptor antagonism, relate to different theories of schizophrenia and are not the primary drivers of the antipsychotic effect in mesolimbic and cortical regions. D1 receptor binding is less central to the classic antipsychotic action in these particular pathways. The crucial point for atypical profiles is that D2 blockade occurs alongside 5-HT2A antagonism, but the binding most directly tied to the antipsychotic effect in these regions remains D2.

Dopamine D2 receptor binding in the mesolimbic and cortical pathways is what mediates the antipsychotic effects in those brain regions. Blocking D2 receptors reduces the dopamine overactivity that contributes to positive symptoms, which is why D2 antagonism is central to antipsychotic action.

Atypical antipsychotics differ by adding other receptor interactions, especially 5-HT2A antagonism, which helps modulate dopamine release in neighboring circuits and reduces motor side effects. So the D2 binding is the key lever for the antipsychotic effect in these regions, with the atypical advantage coming from the broader receptor profile that includes 5-HT2A inhibition.

Other bindings, like NMDA receptor antagonism, relate to different theories of schizophrenia and are not the primary drivers of the antipsychotic effect in mesolimbic and cortical regions. D1 receptor binding is less central to the classic antipsychotic action in these particular pathways. The crucial point for atypical profiles is that D2 blockade occurs alongside 5-HT2A antagonism, but the binding most directly tied to the antipsychotic effect in these regions remains D2.